Improving Oncology Clinical Trial Matching and Enrollment With AI
Drs. Matthew Kurian and Arturo Loaiza-Bonilla discuss how Massive Bio uses neurosymbolic and multi-agent AI to improve oncology clinical trial matching and enro...
View MoreESMO Congress 2026
AI in Oncology: Balancing Innovation and Clinical Validation
Matthew Kurian, MD, and Arturo Loaiza-Bonilla, MD, examine the rapid growth of AI in oncology and whether clinical validation can keep pace with innovation. The...
View More
Latest Conference News
AI Pathology Assays in Breast Cancer: Predicting Chemotherapy Benefit
Matthew Kurian, MD, and Arturo Loaiza-Bonilla, MD, examine how AI-powered pathology assays could help predict chemotherapy benefit in breast cancer using a sing...
View More
Validating AI for Clinical Decision-Making in Oncology
Drs. Matthew Kurian and Arturo Loaiza-Bonilla discuss the challenges of validating AI tools for clinical decision-making in oncology. They explore retrospective...
View More
HERON-Lung01: Ruzaltatug Rezetecan Improves PFS Versus Chemotherapy After EGFR-TKI Progression in NSCLC
Interim results from the phase 3 HERON-Lung01 trial, presented at the ESMO 2026 Congress and published concurrently in The Lancet, show that ruzaltatug rezeteca...
View More
MOIO: Reduced-Frequency Immunotherapy Fails to Establish PFS Noninferiority, Shows Survival Concern
Investigators presented interim results from MOIO, an academic phase III randomized noninferiority trial, at the ESMO 2026 Congress in Madrid. The study evaluat...
View More
TroFuse-005: Sacituzumab Tirumotecan Improves PFS and OS in Previously Treated Endometrial Cancer
Results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial, presented at the European Society of Medical Oncology Congress 2026 in Madrid, show that sacituz...
View More
TUXEDO-3: Review with Dr. Matthias Preusser
Matthias Preusser, MD, PHD, reviews TUXEDO-3 findings demonstrating promising CNS activity with HER3-DXd in patients with brain metastases and leptomeningeal di...
View More
CLARITY-Gastric 01: Sonesitatug Vedotin Improves OS in Previously Treated CLDN18.2-Positive Gastroesophageal Cancer
Results from the phase 3 CLARITY-Gastric 01 (CG-01) trial showed that sonesitatug vedotin (Sone-Ve), a CLDN18.2-targeting antibody-drug conjugate, significantly...
View More